$CWNM The biological activities of TPCs are transduced through a novel tissue protective cytokine receptor identified by Warren scientists. Warren has licensed the worldwide development and commercialization rights to the central and peripheral nervous system indications of its TPCs other than ophthalmic and diabetes to the Danish pharmaceutical company H. Lundbeck A/S.